Gilead Sciences (GILD) to Release Earnings on Thursday

Gilead Sciences (NASDAQ:GILD - Get Free Report) will likely be issuing its quarterly earnings data after the market closes on Thursday, April 24th. Analysts expect the company to announce earnings of $1.73 per share and revenue of $6.77 billion for the quarter. Gilead Sciences has set its FY 2025 guidance at 7.700-8.100 EPS.Individual that wish to register for the company's earnings conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts expect Gilead Sciences to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Trading Down 0.4 %

Shares of NASDAQ GILD traded down $0.39 during mid-day trading on Friday, hitting $104.49. The stock had a trading volume of 8,066,368 shares, compared to its average volume of 7,515,503. The firm has a market cap of $130.10 billion, a P/E ratio of 282.40, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business has a 50 day moving average price of $108.99 and a two-hundred day moving average price of $97.30. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $119.96.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 3.02%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio is 854.05%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at approximately $17,893,713.60. The trade was a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 302,785 shares of company stock valued at $30,540,875. Corporate insiders own 0.27% of the company's stock.

Institutional Trading of Gilead Sciences

A hedge fund recently raised its stake in Gilead Sciences stock. Brighton Jones LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,359 shares of the biopharmaceutical company's stock after purchasing an additional 2,450 shares during the quarter. Brighton Jones LLC's holdings in Gilead Sciences were worth $1,326,000 as of its most recent filing with the Securities & Exchange Commission. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on GILD shares. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Oppenheimer raised their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a report on Tuesday, March 4th. BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.